Topotecan (Page 2 of 5)

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Myelosuppression [see Warnings and Precautions (5.1)]
  • Interstitial Lung Disease [see Warnings and Precautions (5.2)]
  • Extravasation and Tissue Injury [see Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in Warnings and Precautions reflect exposure to topotecan from eight trials in which 879 patients with ovarian cancer or small cell lung cancer (SCLC) received topotecan 1.5 mg/m2 by intravenous infusion daily for 5 consecutive days, starting on Day 1 of a 21 day cycle and from one trial (Study GOG 0179) in which 147 patients with cervical cancer received topotecan 0.75 mg/m2 by intravenous infusion daily on Days 1, 2, and 3, with cisplatin 50 mg/m2 by intravenous infusion on Day 1, of a 21 day cycle.

Ovarian Cancer

The safety of topotecan was evaluated in a randomized trial conducted in 226 patients with metastatic ovarian cancer (Study 039) [see Clinical Studies (14.1)]. Table 1 shows the incidence of Grade 3 and 4 hematologic and non-hematologic adverse reactions that occurred in patients receiving topotecan.

Table 1. Adverse Reactions Occurring in ≥ 5% of Patients with Ovarian Cancer in Study 039

Adverse Reaction

Topotecan

(n = 112)

Paclitaxel (n = 114)

Grade 3 to 4 (%)

Grade 3 to 4 (%)

Hematologic

Grade 4 neutropenia (< 500/mm3)

80

21

Grade 3 or 4 anemia (Hgb < 8 g/dL)

Grade 4 thrombocytopenia (< 25,000/mm3)

41

27

6

3

Febrile neutropenia

23

4

Non-Hematologic

Infections

Sepsisa

5

2

Respiratory, thoracic, and mediastinal

Dyspnea

6

5

Gastrointestinal

10

3

Vomiting

Nausea

10

2

Diarrhea

6

1

Abdominal pain

5

4

Intestinal obstruction

5

4

Constipation

5

0

General and administrative site conditions

7

6

Fatigue

Painb

5

7

Asthenia

5

3

a Death related to sepsis occurred in 2% of patients receiving topotecan and 0% of patients receiving paclitaxel.

b Pain includes body pain, skeletal pain, and back pain.

Small Cell Lung Cancer (SCLC)

The safety of topotecan was evaluated in randomized, comparative trial in patients with recurrent or progressive SCLC (Study 090) [see Clinical Studies (14.2)]. Table 2 shows the Grade 3 or 4 hematologic and non-hematologic adverse reactions in patients with SCLC.

Table 2. Adverse Reactions Occurring in ≥ 5% of Patients with Small Cell Lung Cancer in Study 090

Adverse Reactions

Topotecan

(n = 107)

CAV c (n = 104)

Grades 3 to 4 (%)

Grades 3 to 4 (%)

Hematologic

Grade 4 neutropenia (< 500/mm3)

70

72

Grade 3 or 4 anemia (Hgb < 8 g/dL)

Grade 4 thrombocytopenia (< 25,000/mm3)

42

29

20

5

Febrile neutropenia

28

26

Non-Hematologic

Infections

Sepsisa

5

5

Respiratory, thoracic, and mediastinal

9

14

Dyspnea

Pneumonia

8

6

Gastrointestinal

8

6

Nausea

Abdominal pain

6

4

General and administrative site conditions

9

7

Asthenia

Fatigue

6

10

Painb

5

7

a Death related to sepsis occurred in 3% of patients receiving topotecan and 1% of patients receiving CAV.

b Pain includes body pain, skeletal pain, and back pain.

c CAV = cyclophosphamide, doxorubicin and vincristine.

Hepatobiliary Disorders in Ovarian and Small Cell Lung Cancer

Based on the combined experience of 453 patients with metastatic ovarian cancer and 426 patients with SCLC treated with topotecan, Grade 3 or 4 increases aspartate transaminase (AST) or alanine transaminase (ALT) occurred in 4% and Grade 3 or 4 elevated bilirubin occurred in less than 2%.

Cervical Cancer

The safety of topotecan was evaluated in a comparative trial of topotecan with cisplatin versus cisplatin as a single agent in patients with cervical cancer (Study GOG 0179). Table 3 shows the hematologic and non-hematologic adverse reactions in patients with cervical cancer.

Table 3. Adverse Reactions Occurring in ≥ 5% of Patients with Cervical Cancer (Between-Arm Difference ≥ 2%)a in Study GOG 0179

Adverse Reaction

Topotecan

with Cisplatin

(n = 140)

%

Cisplatin (n = 144)

%

Hematologic

Neutropenia

26

1

Grade 3 (< 1,000 to 500/mm3)

Grade 4 (< 500/mm3)

48

1

Anemia

34

19

Grade 3 (Hgb < 8 to 6.5 g/dL)

Grade 4 (Hgb < 6.5 g/dL)

6

3

Thrombocytopenia

26

3

Grade 3 (< 50,000 to 10,000/mm3)

Grade 4 (< 10,000/mm3)

7

0

Non-Hematologic b ,c

General and administrative site conditions

69

62

Constitutionald

Paine

59

50

Gastrointestinal

40

37

Vomiting

Stomatitis-pharyngitis

6

0

Other

63

56

Dermatology f

48

20

Infection

Febrile neutropeniaf

28

18

Cardiovascular f

25

15

a Includes patients who were eligible and treated.

b Severity based on using National Cancer Institute (NCI) Common Toxicity Criteria (CTC), Version 2.0.

c Grades 1 through 4 only. There were 3 patients who experienced deaths with investigator-designated attribution. The first patient experienced a Grade 5 hemorrhage in which the drug-related thrombocytopenia aggravated the event. A second patient experienced bowel obstruction, cardiac arrest, pleural effusion, and respiratory failure which were not treatment-related but probably aggravated by treatment. A third patient experienced a pulmonary embolism and adult respiratory distress syndrome; the latter was indirectly treatment-related.

d Constitutional includes fatigue (lethargy, malaise, asthenia), fever (in the absence of neutropenia), rigors, chills, sweating, and weight gain or loss.

e Pain includes abdominal pain or cramping, arthralgia, bone pain, chest pain (non-cardiac and non-pleuritic), dysmenorrhea, dyspareunia, earache, headache, hepatic pain, myalgia, neuropathic pain, pain due to radiation, pelvic pain, pleuritic pain, rectal or perirectal pain, and tumor pain.

f High-level terms were included if the between-arm difference was ≥ 10%.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.